Replies to post #210841 on Biotech Values

[ronpopeil]

$34

[DewDiligence]

Fresenius Kabi acquires AKRX for $34/sh in cash—a 35% premium to AKRX’s latest “unaffected” share price on 4/6/17 (#msg-130304273):

http://finance.yahoo.com/news/fresenius-kabi-acquire-akorn-205800399.html

The nominal deal value (including assumption of debt) is $4.75B. Due to international regulatory approvals, the deal is not expected to close until early 2018.

Fresenius Kabi is a wholly-owned subsidiary of the global healthcare giant, Fresenius SE & Co. KGaA (FRE.DE). (FMS, the dialysis company, is 31% owned by FRE.DE.)